The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer
Open accessAbstract
Background: Hereditary leiomyomatosis and renal cell cancer (HLRCC; OMIM 605839) is the predisposition to develop smooth muscle tumours of the skin and uterus and/or renal cancer and is associated with mutations in the fumarate hydratase gene (FH). Here we characterise the clinical and genetic features of 21 new families and present the first report of two African-American families with HLRCC. Methods: Using direct sequencing analysis we identified FH germline mutations in 100% (21/21) of new families with HLRCC. Results: We identified 14 germline FH mutations (10 missense, one insertion, two nonsense, and one splice site) located along the entire length of the coding region. Nine of these were novel, with six missense (L89S, R117G, R190C, A342D, S376P, Q396P), one nonsense (S102X), one insertion (111insA), and one splice site (138+1G>C) mutation. Four unrelated families had the R58X mutation and five unrelated families the R190H mutation. Of families with HLRCC, 62% (13/21) had renal cancer and 76% (16/21) cutaneous leiomyomas. Of women FH mutation carriers from 16 families, 100% (22/22) had uterine fibroids. Our study shows that expression of cutaneous manifestations in HLRCC ranges from absent to mild to severe cutaneous leiomyomas. FH mutations were associated with a spectrum of renal tumours. No genotype-phenotype correlations were identified. Conclusions: In combination with our previous report, we identify 31 different germline FH mutations in 56 families with HLRCC (20 missense, eight frameshifts, two nonsense, and one splice site). Our FH mutation detection rate is 93% (52/56) in families suspected of HLRCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735 · cited 1×
“When normal oxygen levels are present this complex binds to HIF1alpha and HIF2- alpha for ubiquitin–mediated degradation [23].”
BackgroundPrevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010.
Schrag, S. D., Gorwitz, R. J., Fultz-Butts, K., & Schuchat, A. (2002) · PubMed · Cited by 3,349
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 2×
“ROS generation does not appear to be involved in either fumarate or succinatedependent HIF induction [25, 26].”
BackgroundThe Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Stewart, E. A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03622-9 · Cited by 1,031
Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958
Self-citationVariation in the Incidence of Uterine Leiomyoma Among Premenopausal Women by Age and Race
Marshall, L. (1997) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(97)00534-6 · Cited by 889
Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
Kibel, A., Iliopoulos, O., DeCaprio, J. A., & Kaelin, W. G. (1995) · Science · doi:10.1126/science.7660130 · Cited by 671
Inherited susceptibility to uterine leiomyomas and renal cell cancer
Launonen, V., Vierimaa, O., Kiuru, M., Isola, J., Roth, S., Pukkala, E., Sistonen, P., Herva, R., & Aaltonen, L. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633798 · Cited by 669
Toro, J. R., Nickerson, M. L., Wei, M.-H., Warren, M. B., Glenn, G. M., Turner, M. L., Stewart, L., Duray, P., Tourre, O., Sharma, N., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/376435 · Cited by 634
Self-citationInhibition of Transcription Elongation by the VHL Tumor Suppressor Protein
Duan, D. R., Pause, A., Burgess, W. H., Aso, T., Chen, D. Y. T., Garrett, K. P., Conaway, R. C., Conaway, J. W., Linehan, W. M., & Klausner, R. D. (1995) · Science · doi:10.1126/science.7660122 · Cited by 568
Self-citationPause, A., Lee, S., Worrell, R. A., Chen, D. Y. T., Burgess, W. H., Linehan, W. M., & Klausner, R. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2156 · Cited by 493
Self-citationVanharanta, S., Buchta, M., McWhinney, S. R., Virta, S. K., Peçzkowska, M., Morrison, C. D., Lehtonen, R., Januszewicz, A., Järvinen, H., Juhola, M., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/381054 · Cited by 389
Alam, N. A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg148 · Cited by 324
Hereditary paraganglioma targets diverse paraganglia: Table 1
Baysal, B. E. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.9.617 · Cited by 235
Kiuru, M., Launonen, V., Hietala, M., Aittomäki, K., Vierimaa, O., Salovaara, R., Arola, J., Pukkala, E., Sistonen, P., Herva, R., et al. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61757-9 · Cited by 209
The von Hippel-Lindau Tumor Suppressor Gene: Implications and Therapeutic Opportunities
Elias, R., Zhang, Q., & Brugarolas, J. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000480 · Cited by 205
The von Hippel–Lindau Tumor Suppressor Gene
Kondo, K., & Kaelin, W. G. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5139 · Cited by 203
McClintock, D. S., Santore, M. T., Lee, V. Y., Brunelle, J., Budinger, G. R. S., Zong, W.-X., Thompson, C. B., Hay, N., & Chandel, N. S. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.94-104.2002 · Cited by 184
Bourgeron, T., Chretien, D., Poggi-Bach, J., Doonan, S., Rabier, D., Letouzé, P., Munnich, A., Rötig, A., Landrieu, P., & Rustin, P. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117261 · Cited by 160
Chang, W.-K., Yang, K. D., Chuang, H., Jan, J.-T., & Shaio, M.-F. (2002) · Clinical Immunology · doi:10.1006/clim.2002.5257 · Cited by 160
Alam, N. A., Bevan, S., Churchman, M., Barclay, E., Barker, K., Jaeger, E. E. M., Nelson, H. M., Healy, E., Pembroke, A. C., Friedmann, P. S., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/320124 · Cited by 160
The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase
Pollard, P., Wortham, N., & Tomlinson, I. (2003) · Annals of Medicine · doi:10.1080/07853890310018458 · Cited by 159
A simple spectrophotometric assay for fumarate hydratase in crude tissue extracts
Hatch, M. D. (1978) · Analytical Biochemistry · doi:10.1016/0003-2697(78)90299-3 · Cited by 125
Gellera, C., Uziel, G., Rimoldi, M., Zeviani, M., Laverda, A. M., Carrara, F., & DiDonato, S. (1990) · Neurology · doi:10.1212/wnl.40.3_part_1.495 · Cited by 94
Molecular Analysis and Prenatal Diagnosis of Human Fumarase Deficiency
Coughlin, E. M., Christensen, E., Kunz, P. L., Krishnamoorthy, K. S., Walker, V., Dennis, N. R., CHALMERS, R. A., Elpeleg, O. N., Whelan, D. T., Pollitt, R. J., et al. (1998) · Molecular Genetics and Metabolism · doi:10.1006/mgme.1998.2684 · Cited by 78
The von Hippel-Lindau tumor suppressor gene
Decker, H. J., Weidt, E. J., & Brieger, J. (1997) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(96)00296-8 · Cited by 69
Amplification of glutamate-induced oxidative stress
Savolainen, K., Loikkanen, J. J., & Naarala, J. (1995) · Toxicology Letters · doi:10.1016/0378-4274(95)03490-0 · Cited by 49
Poncelet, C., Madélénat, P., Feldmann, G., Walker, F., & Daraï, É. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03301-0 · Cited by 41
Cited by
Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M., Trepel, J., Zbar, B., Toro, J., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.017 · Cited by 958
Self-citationThe genetic basis of kidney cancer: a metabolic disease
Linehan, W. M., Srinivasan, R., & Schmidt, L. S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.47 · Cited by 744
Self-citationSuccinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer
King, A., Selak, M. A., & Gottlieb, E. (2006) · Oncogene · doi:10.1038/sj.onc.1209594 · Cited by 672
Hampel, H., Bennett, R. L., Buchanan, A., Pearlman, R., & Wiesner, G. L. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.147 · Cited by 587
The emerging role and targetability of the TCA cycle in cancer metabolism
Anderson, N. M., Mucka, P., Kern, J. G., & Feng, H. (2018) · Protein & Cell · doi:10.1007/s13238-017-0451-1 · Cited by 556
Metadata
- Authors
- Wei, M.-H., Toure, O., Glenn, G. M., Pithukpakorn, M., Neckers, L., Stolle, C., Choyke, P., Grubb, R., Middelton, L., Turner, M. L., Walther, M. M., Merino, M. J., Zbar, B., Linehan, W. M., & Toro, J. R.
- Venue
- Journal of Medical Genetics
- Publisher
- BMJ
- Published
- 2005-06-03
- Volume
- 43
- Issue
- 1
- Pages
- 18-27
- ISSN
- 0022-2593 (ISSN-L)
- 1468-6244
- OpenAlex
- W2164311435
- Cited by
- 313
- References
- 29
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.